GETT
Gett, the leading corporate Ground Transportation Management (GTM) platform and B2B marketplace, today announced it is furthering its efforts to enable its clients to reduce CO2 emissions by delivering sustainable transportation options for its enterprise clients and their employees.
Gett’s platform now allows enterprise clients in the UK to adopt an employee travel policy consisting solely of electric fleets running 24 hours a day in central London, thus enabling companies to better track, control and reduce CO2 emissions from business travel. Gett has been able to extend this service through both more TX Electric taxis and more fleet partners, including Ola and Green Tomato who provide eco-travel options for business clients.
This new platform capability complements Gett’s existing Gett Green program in the United Kingdom. Through its existing partnership with EcoAct, Gett helps offset enterprise clients’ annual CO2 emissions from vehicle rides. EcoAct’s CO2 offsetting program is based on three accredited projects: wind power generation in India, peatland conservation and restoration, and Cambodian rainforest protection. Each project aligns to specific Sustainable Development Goals (SDGs) as Gett supports its enterprise clients in achieving a more sustainable future. In addition, B2C riders can select from numerous eco-travel options available on the Gett app—Gett Electric (to ride in a TX Electric taxi) and Gett Green (to donate 20p from total ride fare to help fund green projects in London). In May 2021, Gett signed a new Gett Green partner, Trees for Cities. Trees for Cities is a London-based environmental charity that has planted more than one million trees to improve air quality in urban areas. For more on Gett Green and Gett’s commitment to sustainability, visit Gett’s website .
Dave Waiser, CEO and co-founder of Gett, said: “We are delighted to offer more sustainability initiatives at Gett as we strive to reduce CO2 emissions and support our enterprise clients in achieving their sustainability goals. With corporate travel resuming, businesses have greater responsibility for employee transportation. As a global platform, we are in the fortunate position to take action to reduce the impact of pollution in the cities we love and provide businesses travelers with more sustainable transportation choices.”
About Gett
Gett is a technology platform focused on corporate Ground Transportation Management (GTM) in a market worth $100B globally. Gett is the GTM category leader and serves more than a quarter of Fortune 500 companies. Gett’s cloud-based software aggregates existing transportation providers onto a single platform, and helps business manage all their ground transportation spend. Additionally, Gett expands companies’ coverage by connecting them to a grid of transportation providers globally. Gett organizes corporate fleet, ride-hailing, taxi, and limo providers on one platform and optimizes the entire employee experience, from booking and riding to invoicing and analytics, to save businesses time and money. Founded in 2010 and headquartered in London, Gett has raised more than $750M in funding to date, including more than $300M from the Volkswagen Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005431/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom